The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations

The choice of a first-line therapy for lung cancer is a crucial decision that can impact the survival as well as the quality of life of a patient. Inhibitors of epidermal growth factor receptor (EGFR) such as afatinib, erlotinib, and gefitinib have previously been used to treat non-small cell lung c...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chien-Ying, Wang, Chih-Liang, Li, Shih-Hong, Hsu, Ping-Chih, Chen, Chih-Hung, Lin, Ting-Yu, Kuo, Chih-Hsi, Fang, Yueh-Fu, Ko, How-Wen, Yu, Chih-Teng, Yang, Tai-Yun, Yang, Cheng-Ta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722588/
https://www.ncbi.nlm.nih.gov/pubmed/29228636
http://dx.doi.org/10.18632/oncotarget.18746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722588/
https://www.ncbi.nlm.nih.gov/pubmed/29228636
http://dx.doi.org/10.18632/oncotarget.18746

Ejemplares similares